CGEN
Price
$1.51
Change
-$0.08 (-5.03%)
Updated
Dec 18 closing price
63 days until earnings call
INNMF
Price
$0.06
Change
-$0.00 (-0.00%)
Updated
Dec 16 closing price
Ad is loading...

CGEN vs INNMF

Header iconCGEN vs INNMF Comparison
Open Charts CGEN vs INNMFBanner chart's image
Compugen
Price$1.51
Change-$0.08 (-5.03%)
Volume$485.68K
CapitalizationN/A
Amplia Therapeutics
Price$0.06
Change-$0.00 (-0.00%)
Volume$11.24K
CapitalizationN/A
CGEN vs INNMF Comparison Chart
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. INNMF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and INNMF is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (CGEN: $1.51 vs. INNMF: $0.05)
Brand notoriety: CGEN and INNMF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 139% vs. INNMF: 61%
Market capitalization -- CGEN: $134.94M vs. INNMF: $20.75M
CGEN [@Biotechnology] is valued at $134.94M. INNMF’s [@Biotechnology] market capitalization is $20.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 0 FA rating(s) are green whileINNMF’s FA Score has 0 green FA rating(s).

  • CGEN’s FA Score: 0 green, 5 red.
  • INNMF’s FA Score: 0 green, 5 red.
According to our system of comparison, both CGEN and INNMF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 4 TA indicator(s) are bullish.

  • CGEN’s TA Score: 4 bullish, 2 bearish.

Price Growth

CGEN (@Biotechnology) experienced а -5.63% price change this week, while INNMF (@Biotechnology) price change was +8.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.12%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was -1.61%.

Reported Earning Dates

CGEN is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-7.12% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($135M) has a higher market cap than INNMF($20.7M). INNMF YTD gains are higher at: 5.465 vs. CGEN (-23.737).
CGENINNMFCGEN / INNMF
Capitalization135M20.7M652%
EBITDAN/AN/A-
Gain YTD-23.7375.465-434%
P/E Ratio50.33N/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CGEN vs INNMF: Fundamental Ratings
CGEN
INNMF
OUTLOOK RATING
1..100
1728
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
4354
P/E GROWTH RATING
1..100
52100
SEASONALITY SCORE
1..100
n/a3

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INNMF's Valuation (36) in the null industry is somewhat better than the same rating for CGEN (75) in the Biotechnology industry. This means that INNMF’s stock grew somewhat faster than CGEN’s over the last 12 months.

INNMF's Profit vs Risk Rating (98) in the null industry is in the same range as CGEN (100) in the Biotechnology industry. This means that INNMF’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (96) in the Biotechnology industry is in the same range as INNMF (97) in the null industry. This means that CGEN’s stock grew similarly to INNMF’s over the last 12 months.

CGEN's Price Growth Rating (43) in the Biotechnology industry is in the same range as INNMF (54) in the null industry. This means that CGEN’s stock grew similarly to INNMF’s over the last 12 months.

CGEN's P/E Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for INNMF (100) in the null industry. This means that CGEN’s stock grew somewhat faster than INNMF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGEN
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Declines
ODDS (%)
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
View a ticker or compare two or three
Ad is loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL248.05-5.43
-2.14%
Apple
SPY586.28-18.01
-2.98%
SPDR® S&P 500® ETF Trust
BTC.X100041.540000-6099.062500
-5.75%
Bitcoin cryptocurrency
TSLA440.13-39.73
-8.28%
Tesla
GME28.55-2.71
-8.67%
GameStop Corp

CGEN and

Correlation & Price change

A.I.dvisor tells us that CGEN and CRNX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CGEN and CRNX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
-5.03%
CRNX - CGEN
33%
Poorly correlated
-5.92%
ALDX - CGEN
32%
Poorly correlated
-8.44%
IMMP - CGEN
31%
Poorly correlated
+1.88%
SYRS - CGEN
30%
Poorly correlated
-0.10%
XOMA - CGEN
29%
Poorly correlated
-6.93%
More

INNMF and

Correlation & Price change

A.I.dvisor tells us that INNMF and CGEN have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INNMF and CGEN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INNMF
1D Price
Change %
INNMF100%
N/A
CGEN - INNMF
24%
Poorly correlated
-5.03%
ALVR - INNMF
24%
Poorly correlated
-1.53%
HOFBF - INNMF
22%
Poorly correlated
N/A
EXEL - INNMF
21%
Poorly correlated
-2.97%
ARMP - INNMF
21%
Poorly correlated
-2.50%
More